A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

NCT02110355 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancy
Advanced Solid Tumors
Cancer
Oncology
Oncology Patients
Tumors
Melanoma

Interventions

DRUG: AMG 232
DRUG: Trametinib
DRUG: Dabrafenib

Sponsor

Kartos Therapeutics, Inc.

Collaborators

[object Object]